Front. Microbiol. Frontiers in Microbiology Front. Microbiol. 1664-302X Frontiers Media S.A. 10.3389/fmicb.2022.1100290 Microbiology Correction Corrigendum: Metabolomic analysis in spondyloarthritis: A systematic review Huang Tianwen 1 2 3 † Pu Yaoyu 1 2 3 † Wang Xiangpeng 1 2 3 Li Yanhong 1 2 3 Yang Hang 1 2 3 Luo Yubin 1 2 3 * ‡ Liu Yi 1 2 3 * ‡ 1Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China 2Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China 3Institute of Immunology and Inflammation, Frontiers Science Center for Disease Related Molecular Network, West China Hospital, Chengdu, China

Edited and reviewed by: M. Pilar Francino, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Spain

 *Correspondence: Yubin Luo ✉luoyubin2016@163.com Yi Liu ✉yi2006liu@163.com

This article was submitted to Microbial Symbioses, a section of the journal Frontiers in Microbiology

†These authors have contributed equally to this work

‡ORCID: Yubin Luo orcid.org/0000-0002-7669-1579

Yi Liu orcid.org/0000-0002-9258-3594

 12 12 2022 2022 13 1100290 16 11 2022 30 11 2022 Copyright © 2022 Huang, Pu, Wang, Li, Yang, Luo and Liu. 2022 Huang, Pu, Wang, Li, Yang, Luo and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Metabolomic analysis in spondyloarthritis: A systematic review by Huang, T., Pu, Y., Wang, X., Li, Y., Yang, H., Luo, Y., and Liu, Y. (2022). Front. Microbiol. 13:965709. doi: 10.3389/fmicb.2022.965709 spondyloarthritis ankylosing spondylitis metabolomics biomarkers dysbiosis

In the published article, there was an error. We mistakenly described the trend of changes in the levels of some metabolites after treatment of SpA patients.

A correction has been made to Results, “Dynamic alterations in the metabolic profile before and after treatment of spondyloarthritis,” Paragraphs 2 and 4. These sentences previously stated:

“Kapoor et al. (2013) and Bogunia-Kubik et al. (2021) found elevated levels of isobutyrate and acetone in AS as well as elevated levels of acetate in PsA after TNFi therapy. Decreased levels of amino acids, including histidine, leucine and phenylalanine, were also found in AS patients after therapy. Another study including PsA patients receiving TNFi therapy showed higher levels of glutamine than those observed at baseline. Additionally, the two studies both found decreased creatine and creatinine levels in SpA patients after treatment.”

And

“In addition, in the serum of JIA patients, MTX therapy increased the level of omega-3 unsaturated fatty acids (docosahexanoic acid and linoleic acid), which are anti-inflammatory mediators.”

The corrected sentence appears below:

“Kapoor et al. (2013) and Bogunia-Kubik et al. (2021) found decreased levels of isobutyrate and acetone in AS as well as decreased levels of acetate in PsA after TNFi therapy. Elevated levels of amino acids, including histidine, leucine and phenylalanine, were also found in AS patients after therapy. Another study including PsA patients receiving TNFi therapy showed lower levels of glutamine than those observed at baseline. Additionally, the two studies both found elevated creatine and creatinine levels in SpA patients after treatment.”

And

“In addition, in the serum of JIA patients, MTX therapy reduced the level of omega-3 unsaturated fatty acids (docosahexanoic acid and linoleic acid), which are anti-inflammatory mediators.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Bogunia-Kubik K. Wojtowicz W. Swierkot J. Mielko K. A. Qasem B. Wielinska J. . (2021). Disease differentiation and monitoring of anti-TNF treatment in rheumatoid arthritis and spondyloarthropathies. Int. J. Mol. Sci. 22:7389. 10.3390/ijms2214738934299006 Kapoor S. R. Buckley C. D. Raza K. Filer A. Fitzpatrick M. A. Young S. P. . (2013). Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum. 65, 1448–1456. 10.1002/art.3792123460124